Zynex Analyst Ratings
RBC Capital Reiterates Outperform on Zynex, Maintains $15 Price Target
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Zynex (ZYXI)
RBC Capital Reaffirms Their Buy Rating on Zynex (ZYXI)
Zynex Analyst Ratings
Maintaining Buy Rating for Zynex on Strong Growth and Positive Outlook
RBC Capital Remains a Buy on Zynex (ZYXI)
Zynex (ZYXI) Receives a Buy From RBC Capital
RBC Raises Price Target on Zynex to $15 From $13, Keeps Outperform Rating
RBC Capital Remains a Buy on Zynex (ZYXI)
Zynex Analyst Ratings
Buy Rating Affirmed for Zynex on Strong Growth Prospects and Financial Health
Analysts Offer Insights on Healthcare Companies: Zynex (ZYXI) and Privia Health Group (PRVA)
RBC Capital Reaffirms Their Buy Rating on Zynex (ZYXI)
Zynex Trades Higher After Outperform Rating at RBC Capital on Growth Prospects
Zynex Analyst Ratings
RBC Initiates Zynex at Outperform With $13 Price Target, Cites 'Favorable' Financial Profile, 'Attractive Risk-Reward'
Analysts Offer Insights on Healthcare Companies: Zynex (ZYXI) and Arcutis Biotherapeutics (ARQT)
H.C. Wainwright Remains a Buy on Zynex (ZYXI)
The Latest Analyst Ratings for Zynex